RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated a Sector Perform rating on Gilead Sciences and maintained a $75 price target.
October 29, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated its Sector Perform rating for Gilead Sciences, maintaining a $75 price target, indicating a neutral outlook.
The reiteration of a Sector Perform rating and maintenance of the $75 price target by RBC Capital suggests a neutral stance on Gilead Sciences. This indicates that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100